~~<i id='764F6017EC'><strike id='764F6017EC'><tt id='764F6017EC'><pre id='764F6017EC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：knowledge 2025-09-06 02:06:07 - browse：59

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Reanimated hearts work just as well for transplants, study finds

explore

knowledge

hotspot

AdobeInMay,aNationalPublicRadiostoryasked,“Canachatbothelppeoplewitheatingdisordersaswellasanotherhu

WSS

Millions may soon lose Medicaid when they don't have to

Biden administration plans revamp of organ transplant system

Roche's accidental data boosts hopes for anti

Can medical device makers keep up in the race to treat obesity?

A public health expert passes on football's full body collisions for youths

DeSantis wants to import drugs. Biden’s FDA blasted his plan

hotspot

knowledge

explore

Duchenne breakthrough therapy leaves behind pioneering families

As obesity drug market grows, telehealth companies court payers

Dobbs anniversary: the lost opportunity of abortion as health care

People can get long Covid without testing positive for virus: Study

After affirmative action ruling, medical educators look to 'holistic review'

FDA greenlights medical device to combat bladder issues

Sports medicine is finally prioritizing gender equality

PBMs are inflating the cost of generic drugs. They must be reined in

Jerome Adams on the need for new antivirals for Covid

Senate panel passes drug pricing bills, but drops one PBM reform

explore

Biden administration plans revamp of organ transplant system

Millions may soon lose Medicaid when they don't have to

Trans patients at the end of life deserve respect and dignity

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

explore

knowledge

knowledge

hotspot